Summary of Kang En Bei's Conference Call Company Overview - **Company**: Kang En Bei - **Industry**: Traditional Chinese Medicine and Pharmaceuticals Key Financial Performance - **2026 Q1-Q3 Revenue**: 41.76 billion CNY, a year-on-year increase of 1.27% [3] - **Net Profit**: 5.84 billion CNY, a year-on-year increase of 12.65% [3] - **Gross Margin**: Maintained above 50% in Q1-Q3 2026 [7] - **Net Margin**: Improved, with sales expense ratio reduced from nearly 40% in 2021 to around 31% [7] - **2024 Financial Projections**: Revenue of 65 billion CNY, total profit of 7 billion CNY, total assets of 99 billion CNY, and net assets of 68 billion CNY [7] Product Line Performance - **Traditional Chinese Medicine (TCM)**: Overall growth of 5.37% in Q1-Q3 2026, with the "Chang Yan Ning" series growing over 25% [2][4] - **Health Consumer Products**: Grew by 12.41%, with new products like probiotic freeze-dried powder generating over 40 million CNY in revenue [5] - **Chemical Medicine**: Revenue of 17.2 billion CNY, down 7.16% due to centralized procurement failures and price declines [5][16] Strategic Goals - **2030 "1,118" Strategy**: Targeting revenue of 110 billion CNY (including 20 billion CNY from acquisitions) and net profit of 10 billion CNY (including 2 billion CNY from acquisitions) [6] - **Focus Areas**: Brand renewal, business upgrades, mechanism activation, and integrated development [6] Market Opportunities - **Drivers of Growth**: Aging population, increased health awareness, TCM policy benefits, rise of instant retail, and AI technology [9] - **Future Growth Sources**: Self-health business lines (OTC and health consumer products) expected to drive growth, aiming for an 8% CAGR in OTC and over 10% in health consumer products [19] Integration and Development Measures - **Headquarters Optimization**: Reduced from 16 departments to 11+1 for efficiency [10] - **Business Unit Integration**: Merged TCM and chemical medicine divisions into a prescription drug system [10] - **Consultation with McKinsey**: Engaged to ensure smooth integration [10] Challenges and Responses - **Chemical Medicine Sector**: Facing pressure from centralized procurement policies; strategies include optimizing resources and enhancing market promotion [15][16] - **Market Adaptation**: Focus on brand and cost advantages, with a cautious approach to new drug development [16] Future Plans and Innovations - **BD Strategy**: Focus on acquiring mature brands, innovative drugs, and health consumer products [17][18] - **Raw Material Business**: Aiming to become a leader in specialty raw materials by 2030, with significant market shares in key products [20][21] - **Participation in TCM Procurement**: Leveraging owned planting areas for cost advantages [22] Shareholder Engagement - **Dividend Policy**: Historically high dividend rates, with a commitment to a minimum of 20% cash dividends based on performance [24][25] Leadership and Governance - **New Chairman's Vision**: Emphasis on internal growth and overall competitiveness [27] - **Future Performance Expectations**: Anticipated strong performance in 2026 as part of a new strategic plan [30]